Using IMIG, IVIG, and MSC Therapy as Parallel Pathways to Neuropeptide Cascade Recovery
Somatostatin (SST)-expressing GABAergic interneurons exist in two functionally distinct populations whose roles in immune-dysregulated ASD are opposite in direction but sequentially caused. In the gut, SST-28 is chronically overactive — tonically suppressing the enteroendocrine cascade through opioid peptide-driven CCK overstimulation. In the brain, SST-14-expressing interneurons are silenced — their cAMP→PKA→CREB transcriptional drive suppressed by two converging mechanisms: NF-κB-mediated CREB inhibition driven by chronic cytokine exposure, and Gαi-coupled adenosine receptor suppression of adenylyl cyclase driven by CD26 blockade.
When SST-14 interneurons are silenced by loss of the cAMP→PKA→CREB drive, the downstream neuropeptide cascade — oxytocin, vasoactive intestinal peptide (VIP), and secretin — loses its upstream coordination simultaneously. The observable phenotype cluster of immune-derived autism (IDA) — social, sensory, sleep, and gastrointestinal features — emerges from this single mechanistic node, not from parallel independent deficits.
This paper proposes that IMIG and MSC therapy are parallel upstream pathways to SST-14 transcriptional restoration, each targeting a distinct state of SST-14 interneuron silencing. Three mechanistically distinct states are identified: State 1 (transcriptional silencing, structural integrity preserved — primary target of IMIG/IVIG); State 2 (metabolic exhaustion, structural integrity preserved — requires NAD⁺ precursor repletion and mitochondrial support alongside immunotherapy); and State 3 (partial structural loss — requires MSC-mediated trophic restoration of the interneuron microenvironment). A biomarker-stratified trial framework is proposed with neuropeptide cascade recovery as the primary endpoint.
Three decades of clinical trial failures in ASD — secretin, oxytocin, IVIG in unselected populations — are not evidence of therapeutic futility. They are evidence that downstream neuropeptide replacement cannot succeed when the upstream SST-14 interneuron silencing that disrupted neuropeptide coordination remains unaddressed, and that unselected enrollment dilutes the responsive immune-dysregulated subgroup to statistical insignificance. This paper provides the mechanistic foundation and trial architecture to test the SST-14 restoration hypothesis directly.
Autism spectrum disorder (ASD) affects approximately 1 in 36 children.[1] Despite decades of research, no pharmacological intervention has demonstrated consistent efficacy across the broad ASD population, and the condition is increasingly understood as a collection of distinct biological subtypes that happen to share a behaviorally defined diagnostic boundary.[2]
Among the most mechanistically coherent of these subgroups is one defined by immune dysregulation, chronic neuroinflammation, and aberrant neuroimmune signaling.[3,4,20] Within this subgroup, the somatostatin-14 (SST-14) interneuron has emerged as a convergent node whose silencing produces the coordinated neuropeptide cascade failure — oxytocin, VIP, and secretin simultaneously dysregulated — that maps directly onto the core ASD phenotype cluster of social, sensory, sleep, and gastrointestinal features.
This paper evaluates three therapeutic modalities against the SST-14 silencing target: IVIG as the established immunological precedent; IMIG as a mechanistically equivalent, substantially lower-cost alternative developed by Dr. P.R. Fourie; and mesenchymal stem cell (MSC) therapy as the parallel pathway for State 2 metabolic exhaustion and State 3 partial structural loss. A universal adjunctive metabolic support protocol is proposed across all states. A biomarker-stratified trial framework with neuropeptide cascade recovery as the primary endpoint completes the framework.
The central claim is not that these therapies treat autism. It is that they restore the upstream SST-14 transcriptional drive whose suppression is producing the neuropeptide cascade failure — and that neuropeptide cascade recovery is the correct measure of whether they have worked.
The somatostatin gene encodes a 116-amino-acid preprosomatostatin precursor that is cleaved tissue-specifically into two principal bioactive peptides. SST-28 is the predominant form in intestinal D-cells, where it functions as a paracrine inhibitor of enteroendocrine secretion. SST-14 is the predominant form in cortical, hippocampal, and hypothalamic GABAergic interneurons, where it coordinates the pulsatility and timing of oxytocin, VIP, and secretin release through GABA-mediated disinhibitory circuits.
In immune-dysregulated ASD, these two forms are simultaneously dysregulated in opposite directions through sequential mechanistic causation. In the gut, chronic opioid peptide (casomorphin and gliadorphin) overstimulation of CCK drives SST-28 into sustained overexpression, creating a tonically active brake on the enteroendocrine cascade. In the brain, the same upstream cascade — through NF-κB activation and adenosine accumulation — silences SST-14 interneurons, depriving the neuropeptide cascade of its upstream coordinator.
In the gut, SST-28 is overactive — tonically suppressing the enteroendocrine cascade. In the brain, SST-14 is silenced — failing to coordinate the neuropeptide cascade. Same gene, same precursor, opposite dysfunction, sequential causation.
SST-14 gene expression is driven through a cyclic AMP response element (CRE) in the somatostatin gene promoter. Montminy et al. (J Neurosci 1986)[56] demonstrated that cAMP regulates somatostatin mRNA accumulation in primary diencephalic cultures — establishing the functional link between the cAMP→PKA→CREB signaling chain and SST-14 gene expression. The CRE sequence (5'-TGACGTCA-3') was identified in the somatostatin gene promoter by Montminy et al. (PNAS 1986)[57] as the binding site for CREB, the transcription factor whose phosphorylation by PKA initiates SST-14 gene transcription.
Two independent mechanisms converge to suppress this axis in immune-dysregulated ASD. The first is NF-κB-mediated CREB suppression: pro-inflammatory cytokines activate NF-κB, which outcompetes CREB for CBP (CREB-binding protein) — the co-activator both require to drive gene transcription — and recruits HDAC enzymes to compact the chromatin around the somatostatin gene CRE, making it physically less accessible. The second is Gαi-coupled adenosine receptor suppression of adenylyl cyclase: casomorphin and gliadorphin block CD26 (DPP-IV), preventing adenosine deaminase docking, allowing adenosine to accumulate, and activating inhibitory Gαi-coupled receptors that suppress adenylyl cyclase, depleting cAMP and starving CREB of its PKA-mediated activating signal.
A third independent input suppresses adenylyl cyclase through the same Gαi pathway but via a distinct receptor: casomorphin and gliadorphin also activate mu-opioid receptors (MOR) directly on SST-14 interneurons, producing a second Gαi-coupled adenylyl cyclase suppression at approximately 25–60% inhibition — operating as long as gut-derived opioid peptide load persists, independent of adenosine accumulation. The adenosine (A1/A2A) and mu-opioid Gαi inputs are additive: restoring adenosine clearance alone cannot fully recover cAMP output while opioid peptide load persists. This dual-receptor Gαi suppression explains why both methylation cycle restoration (addressing adenosine) and gut pH correction (reducing casomorphin and gliadorphin production) are required for complete Mechanism 2 relief — and why IMIG, by reducing gut permeability and the cytokine environment, addresses both inputs indirectly over time.
This molecular precision matters clinically: removing the NF-κB-activating cytokine load — through immunoglobulin therapy — relieves one suppressive input and allows CREB to resume driving SST-14 expression. Addressing the CD26 blockade burden — through dietary intervention and IMIG-mediated autoantibody clearance — relieves the second suppressive input. Both must be addressed for durable SST-14 transcriptional recovery.
A partial compensatory mechanism for the adenylyl cyclase suppression exists in females and is absent in prepubertal males. Qiu et al. (J Neurosci 2003)[58] characterized the complete Gq-mER → Gαq → PLC → DAG → PKCδ → adenylyl cyclase VII → cAMP chain in hypothalamic neurons by single-cell RT-PCR. This pathway generates cAMP through a Gαq-mediated route entirely independent of the Gαi suppression that adenosine uses to cut the conventional cAMP supply. Because the somatostatin gene contains a CRE,[56,57] the Gq-mER-generated cAMP drives SST-14 gene transcription through CREB, partially counteracting the NF-κB-mediated CREB suppression simultaneously.
At puberty, testosterone-to-estradiol conversion through brain aromatase provides prepubertal males with their first access to this compensatory pathway — accounting for the spontaneous improvement in social and communicative function that some families report in adolescent males with IDA, and providing a testable molecular prediction: post-pubertal males should show faster IMIG response trajectories than pre-pubertal males of equivalent state assignment.
Three neuropeptide systems whose dysfunction maps directly onto core ASD features are gated by SST-14 interneuron output.
Secretin. Secretin is released from duodenal S-cells in response to luminal acid and fat, and acts on the brain via vagal afferents and direct receptor expression in the cerebellum, hypothalamus, and pituitary. The early clinical observation by Horvath et al. (1998) that secretin infusion produced behavioral improvements in some autistic children, and the subsequent consistent failure of unselected RCTs to replicate this effect, is precisely explained by the SST-14 gate model: secretin infusion cannot restore the circuit timing and social-contextual coupling that SST-14 interneuron coordination of hypothalamic and cerebellar output provides. Replacing the signal downstream of a locked gate cannot pass through the lock.
Oxytocin. SST-14 interneurons in the paraventricular nucleus modulate the timing and amplitude of oxytocin release in response to social and safety signals. When the cAMP→PKA→CREB→SST-14 transcriptional axis is suppressed, PVN SST-14 output is reduced, releasing PVN oxytocin neurons from appropriate inhibitory control — producing aberrant, non-social-contextual oxytocin release and blunted pulsatile responses to genuine social stimuli. Exogenous oxytocin administration cannot restore this circuit-level coordination.
VIP. Cortically, VIP interneurons are the primary disinhibitory arm releasing pyramidal neurons from SST-14-mediated inhibition during appropriate behavioral states. Peripherally, VIP is a key enteric neurotransmitter regulating gut motility, secretion, and mucosal immune responses. When SST-14 interneurons are silenced, the normal VIP-SST-14 push-pull circuit that controls gamma oscillation power and NREM sleep slow-wave activity becomes dysregulated simultaneously with the enteric VIP pathway.
The cluster of social, sensory, sleep, and gastrointestinal features in immune-derived ASD is not a coincidence. It is the predictable consequence of losing the single upstream coordinator — SST-14 — that gates all three downstream systems simultaneously.
Understanding which upstream intervention a patient requires depends on identifying the predominant state of SST-14 interneuron silencing. Three mechanistically distinct states are proposed, each with a distinct biomarker signature and distinct primary therapeutic target.
These states are not mutually exclusive within a given patient. The biomarker profile guides upstream pathway assignment while the adjunct protocol is proposed as a foundational support layer across all states. Most patients with longstanding IDA present with elements of State 1 and State 2 simultaneously.
Intravenous immunoglobulin is the most extensively studied immunological intervention in ASD, with 27 published studies and a meta-analysis demonstrating large effect sizes for improvements in total aberrant behavior and irritability (Cohen's d' = 0.80 and 0.87 respectively) and medium effect sizes for hyperactivity and social withdrawal.[23] The Rossignol and Frye 2021 systematic review provides the most comprehensive analysis, identifying consistent improvements in communication, irritability, hyperactivity, cognition, attention, and social interaction across prospective and retrospective studies. Improvements in pro-inflammatory cytokines including TNF-α were documented in multiple studies.
The loss of improvements when IVIG is stopped — documented in 85% of treated patients in Boris et al. (2005)[24] and consistent across multiple studies — is mechanistically informative: it confirms that the upstream inflammatory drivers remain active during treatment and reassert suppression when immunoglobulin-mediated modulation is withdrawn. This is not a treatment failure — it is evidence that the mechanism is active and responsive, and that ongoing treatment is required for sustained benefit.
Despite its evidence base, IVIG carries significant practical limitations. Annual treatment costs exceed $30,000 per patient in the United States. Administration requires IV access, specialist infusion facilities, and monitoring for infusion reactions — creating logistical barriers that prevent most families globally from accessing treatment. The high peak-trough pharmacokinetic profile of IVIG may produce intermittent immunomodulation rather than the sustained steady-state coverage that chronic neuroinflammation management requires.
IVIG is optimally effective for State 1 SST-14 silencing: its mechanism relieves the NF-κB-CREB transcriptional suppression directly. It does not address the metabolic exhaustion of State 2 or the structural loss of State 3 without adjunctive support. The consistent finding of variable response rates in IVIG trials reflects state heterogeneity in unselected enrollment: State 1 patients respond; State 2 patients respond partially; State 3 patients show limited response to immunotherapy alone.
Intramuscular immunoglobulin delivers pooled polyclonal IgG via intramuscular depot injection, producing sustained serum IgG levels through slow, controlled absorption kinetics rather than the rapid peak-trough profile of IV administration. The pharmacokinetic profile — slower rise, more sustained plateau — may be advantageous for the management of chronic neuroinflammation, where sustained immunomodulation rather than peak-concentration effects is the therapeutic objective. The immunological mechanisms — anti-idiotype antibody neutralization of pathogenic autoantibodies, FcγRIIB upregulation, and cytokine normalization — are shared with IVIG, with the addition of depot-site innate immune priming that may contribute to sustained regulatory effects.
Dr. P.R. Fourie, consultant pediatrician and principal investigator, represents the only published investigator who has documented the clinical use of IMIG specifically in autism spectrum disorder. His combined case report (Fourie & Armstrong, Medical Research Archives 2024)[61] treated 7 children with ASD and 5 with PANS using monthly IMIG injections (0.2ml/kg Intragam, 16%, every 4–6 weeks). Parent-rated improvement scores averaged 2.9 for the ASD group and 4.4 for the PANS group on a −5 to +5 scale. Side effects were minimal — injection-site discomfort resolving within 12 hours in all patients, one episode of nausea in one patient.
This evidence base currently rests on a single published clinician's experience. This is simultaneously a strength — Dr. Fourie is the world expert on IMIG in ASD — and a limitation that makes the proposed controlled pilot trial not merely desirable but scientifically necessary.
The IMIG protocol as developed by Dr. Fourie: 0.2ml/kg body weight Intragam (National Bioproducts Institute, South Africa, 16%) administered intramuscularly to the upper lateral buttock area in an antiseptic manner every 4–6 weeks. The total dose is delivered in two divided injections if the total volume exceeds 7–10ml, based on patient tolerance. Monitoring includes general health checks before and after treatment and parent-completed symptom ratings at each visit.
IMIG shares IVIG's mechanism, state specificity, and response profile — while reducing cost by approximately 95% and eliminating the IV access, specialist facility, and infusion reaction monitoring requirements that make IVIG inaccessible to most families globally.
Mesenchymal stem cells exert their principal therapeutic effects through paracrine secretion rather than engraftment. The MSC secretome includes IDO, PGE2, TGF-β, IL-10, BDNF, NGF, IGF-1, and extracellular vesicles carrying miRNA cargo that reprograms recipient cell gene expression. In the context of immune-dysregulated ASD, three paracrine mechanisms are relevant: Treg induction through IDO and TGF-β, which reduces the NF-κB-activating cytokine load; trophic support of surviving SST-14 interneurons through BDNF and IGF-1; and A1-to-A2 astrocyte repolarization through inhibition of the microglial IL-1α, TNF-α, and C1q signals that maintain A1 polarization.
MSCs are applicable across all three states with different primary mechanisms in each. In State 1, Treg induction and cytokine normalization relieve the NF-κB-mediated CREB suppression with greater durability than IMIG/IVIG alone, potentially reducing the frequency of immunoglobulin administration required for maintenance. In State 2, MSCs provide the metabolic rescue that neither IVIG nor IMIG can access: mitochondrial transfer via tunneling nanotubes delivers functional mitochondria directly to energy-depleted SST-14 interneurons, bypassing the IDO1-driven NAD⁺ depletion that prevents ATP recovery. In State 3, direct evidence from a neuroinflammatory mouse model demonstrates that intranasal MSC therapy restored SST-14-positive interneuron populations in the dentate gyrus and partially recovered social behavior — providing the preclinical proof-of-concept for structural recovery through A1→A2 astrocyte repolarization.
Phase I clinical trials of MSC therapy in ASD have produced cautiously positive signals. A controlled trial found significant improvements in CARS, ABC, and CGI scores in groups receiving combined umbilical cord-derived MSC plus umbilical cord blood infusion versus cord blood alone. A meta-analysis of six clinical trials found significant improvements across behavioral and adaptive functioning measures. The quality of evidence remains limited by small sample sizes and heterogeneous enrollment — the same state-mismatch problem that has confounded IVIG trials. Biomarker-stratified enrollment selecting State 2 and State 3 patients is expected to substantially improve the signal-to-noise ratio.
The adjunct protocol provides the metabolic substrate, antioxidant capacity, and epigenetic conditions without which SST-14 interneuron recovery is biochemically constrained regardless of how effectively the upstream immune burden is addressed. IMIG removes the transcriptional suppression; the adjunct protocol ensures the metabolic infrastructure beneath that removal is capable of responding.
| Agent | Primary Target | SST-14 / Neuropeptide Cascade Rationale | Evidence |
|---|---|---|---|
| Sulforaphane | Nrf2 activation; NF-κB inhibition | Reduces the cytokine-driven NF-κB load suppressing CREB at the somatostatin CRE. Singh et al. (PNAS 2014) RCT: significant improvement in SRS and ABC scores in ASD. | Level 1 — ASD RCT |
| NMN / NR | NAD⁺ precursors; mitochondrial energy | Replenishes NAD⁺ depleted by IDO1-driven kynurenine pathway diversion. Restores mitochondrial ATP production required for SST-14 interneuron tonic firing. Critical for State 2. | Level 2 — mechanistic |
| Tributyrin / C. butyricum | HDAC inhibition; butyrate delivery | HDAC inhibitory-driven SST-14 gene transcription via histone acetylation at the somatostatin CRE — provides a cAMP-CREB-independent route to SST-14 expression. Critical adjunct when both transcriptional mechanisms are suppressed simultaneously. | Level 2 — mechanistic |
| NAC | Glutathione replenishment | Restores the antioxidant capacity depleted by quinolinic acid-driven oxidative stress in SST-14 interneurons. Reduces the oxidative burden that accelerates State 1→2 progression. | Level 1 — ASD RCTs |
| Omega-3 PUFA | SPM substrate; anti-inflammatory resolution | Provides substrate for specialized pro-resolving mediators (SPMs) — the active inflammatory off-switch that terminates LPS-driven cytokine production. Addresses Constitutional Tipping Point 4 (ALOX pathway variants). | Level 1 — ASD evidence |
| Zinc | Parietal cell acid production; DPP-IV support | Restores carbonic anhydrase function in parietal cells, normalizing gastric pH and reducing opioid peptide generation upstream of CD26 blockade. Addresses the founding condition driving adenosine accumulation. | Level 1 — ASD evidence |
| Magnesium | NMDA receptor modulation; ATP substrate | Physiological NMDA receptor channel blocker — reduces quinolinic acid-driven calcium overload in SST-14 interneurons. Mg²⁺-ATP is the substrate form adenylyl cyclase uses to produce cAMP. | Level 1 — ASD evidence |
| Hydroxy-B12 + Folinic acid | Methylation cycle restoration | Addresses the methylation cycle failure driven by adenosine accumulation and CD26 blockade. Hydroxy-B12 specifically addresses the nitric oxide-mediated B12 inactivation pathway documented in ASD. | Level 1 — ASD RCTs |
| Taurine | Mitochondrial membrane; calcium buffering | Protects SST-14 interneuron mitochondria from quinolinic acid-driven calcium overload. Supports the cellular energy environment required for tonic high-frequency SST-14 interneuron firing. | Level 2 — mechanistic |
Two agents warrant particular emphasis. Tributyrin or C. butyricum — rather than sodium butyrate, which is absorbed too early in the GI tract to reach colonocytes — provides HDAC inhibitory-driven SST-14 gene transcription through histone acetylation at the somatostatin CRE: a cAMP-CREB-independent route to SST-14 expression that bypasses both Mechanism 1 and Mechanism 2 suppression. This makes it the uniquely critical adjunct when both transcriptional suppression mechanisms are operating simultaneously.
Null results in unselected IVIG, IMIG, and MSC trials reflect state mismatching: interventions targeting SST-14 transcriptional restoration through specific mechanisms were tested in populations where the target mechanism was present in only a fraction of enrolled patients. The responsive immune-dysregulated subgroup is diluted to statistical insignificance by unselected enrollment. The SOARS-B oxytocin trial (Sikich et al., NEJM 2021, n=290) and the secretin Cochrane review (14 null RCTs) both reflect this population-selection failure, not a failure of the underlying biology.
Two or more of the following criteria are required for eligibility. Thresholds reflect established clinical significance for each assay.
| Biomarker | Threshold | Mechanistic Target |
|---|---|---|
| Neural autoantibody panel (Cunningham Panel) | Any positive: anti-tubulin IgG, anti-lysoganglioside GM1, anti-dopamine D1/D2L, CaM Kinase II ≥130 units | State 1 primary indicator — NF-κB-CREB suppression via autoantibody-driven neuroinflammation |
| Kynurenine:tryptophan (K:T) ratio | >0.08 (HPLC-MS/MS) | Active IDO1-driven tryptophan diversion — NAD⁺ depletion and quinolinic acid production |
| Cytokine elevation | Any two of IL-1β, IL-6, TNF-α above 90th percentile for age | NF-κB-activating cytokine load suppressing CREB at somatostatin gene CRE |
| Lactate:pyruvate ratio | >25 | Mitochondrial respiratory chain dysfunction — State 2 metabolic exhaustion indicator |
| Plasma quinolinic acid | Elevated vs. age-matched controls | Direct excitotoxic driver of SST-14 metabolic stress |
| Homocysteine | >10 μmol/L | CD26-driven methionine synthase rate-limitation — methylation cycle failure |
| Folate receptor autoantibodies | Positive (blocking or binding) | Cerebral folate deficiency independent of dietary intake |
| State | Defining Biomarkers | Primary Intervention | Adjunct Additions |
|---|---|---|---|
| State 1 | Cunningham Panel positive; cytokines elevated; K:T ratio normal or mildly elevated; L:P ratio normal | IMIG or IVIG + adjunct protocol | Standard adjunct protocol |
| State 2 | Any State 1 criteria + K:T ratio >0.12; L:P ratio >25; plasma QUIN elevated | IMIG/IVIG + NMN/NR + taurine + adjunct protocol | NMN/NR priority addition; taurine priority addition |
| State 1+2 Combined | Cunningham Panel positive + K:T >0.12 + L:P >25 | IMIG + MSC + adjunct protocol (full combination) | Full adjunct protocol including NMN/NR and taurine |
| State 3 | Clinical regression history + partial response to prior immunotherapy + State 1 or 2 biomarkers | MSC therapy + IMIG maintenance + adjunct protocol | Full adjunct with extended timeline expectation |
Primary biological endpoints: change in plasma kynurenine:tryptophan ratio; change in serum cytokine panel; change in autoantibody titers; change in lactate:pyruvate ratio. Assessed at baseline, 3, and 6 months. These are the direct molecular measures of whether the SST-14 transcriptional drive has been restored and the downstream cascade has recovered.
Primary functional endpoints: change in plasma oxytocin pulsatility pattern; change in urinary VIP; change in plasma secretin. These are the direct neuropeptide measures of SST-14 interneuron functional output recovery. Secondary behavioral endpoints: SRS-2, ABC, VABS-3, CGI-I assessed at 3 and 6 months.
Trial design: randomized, biomarker-stratified, placebo-controlled pilot. Five arms: IMIG + adjuncts; MSC + adjuncts; IMIG + MSC + adjuncts; adjunct-only control; screen-negative observational cohort. Proposed n=10 per arm, 6-month primary endpoint, 12-month follow-up. Site: TASK Clinical Trials, South Africa (Johann de Bruyn, CEO). Principal Investigator: Dr. P.R. Fourie.
The secretin trials of the late 1990s and early 2000s are the most instructive precedent for this paper's central argument. The initial case report by Horvath et al. (1998) described behavioral improvements in three autistic children following secretin administration for diagnostic endoscopy. The subsequent 14 RCTs of secretin in unselected ASD populations all produced null results. The standard interpretation was that secretin does not work in autism. The SST-14 gate model provides a more precise interpretation: secretin works through a cAMP-mediated signaling pathway that requires adenylyl cyclase activity; in the immune-dysregulated ASD subgroup, adenylyl cyclase is suppressed by Gαi-coupled adenosine receptor activation; secretin cannot generate cAMP through a suppressed adenylyl cyclase; the signal cannot get through the locked gate.
Independent genetic evidence for the State 2 model comes from Dr. Eric M. Morrow's research on glutamate pyruvate transaminase 2 (GPT2). GPT2 is the mitochondrial enzyme that clears synaptic glutamate by converting it to alpha-ketoglutarate for TCA cycle entry. Loss-of-function mutations in GPT2 produce intellectual disability and microcephaly in humans, consistent with the role of mitochondrial glutamate handling in neurodevelopmental outcome. The connection to State 2 SST-14 silencing is direct: when IDO1 is chronically activated in neuroinflammatory ASD, it drives NMDA-mediated glutamate excitotoxicity at SST-14 interneuron synapses; GPT2 is one of the primary mitochondrial enzymes clearing the synaptic glutamate that IDO1 activation elevates. GPT2 loss-of-function mutations provide genetic proof-of-concept that mitochondrial-glutamate dysfunction at the synaptic level causes the kind of neurodevelopmental disability that State 2 predicts — through an acquired rather than genetic mechanism.
Independent support for the three-state model comes from Robert Naviaux's cell danger response (CDR) framework. Chronic activation of P2X7 receptors on microglia drives NLRP3 inflammasome activation and persistent IL-1β production — maintaining the NF-κB-activating cytokine environment that suppresses SST-14 transcription. Naviaux's 2017 phase I/II suramin trial (n=10) produced improvement across all three core ASD domains in all five treated participants at 6 weeks, with gains lost after suramin's 14–15 day half-life. Suramin antagonizes P2Y receptors that couple through Gαi to suppress adenylyl cyclase — the identical Gαi-adenylyl cyclase suppression mechanism the SST-14 cascade framework describes through the adenosine/CD26 arm. The CDR and the three-state SST-14 model represent convergent evidence from independent research lineages arriving at the same biological territory.
| Claim | Level | Basis |
|---|---|---|
| Neuroinflammation in ASD subgroup | Level 1 | Multiple independent human ASD studies; Vargas et al. 2005; Rossignol & Frye 2012 meta-analysis |
| IVIG clinical benefit in immune-dysregulated ASD | Level 1 | Rossignol & Frye 2021 meta-analysis, 27 studies, large effect sizes |
| IMIG clinical benefit in ASD | Level 2 | Fourie & Armstrong 2024 — single published investigator, n=12 |
| cAMP→PKA→CREB→CRE→SST-14 transcriptional axis | Level 1 | Montminy PNAS 1986; Montminy J Neurosci 1986; established molecular biology |
| NF-κB-CREB competition for CBP | Level 2 | Established molecular biology; not directly demonstrated in SST-14 interneurons |
| Estrogen-cAMP compensatory axis | Level 2 | Aronica PNAS 1994; Qiu J Neurosci 2003; established in hypothalamic neurons |
| SST-14 interneuron hypoactivity causes social deficits | Level 2 | Wang et al. Mol Autism 2025 — optogenetic rescue; Luo et al. Mol Autism 2025 — Magel2 model |
| Three-state clinical model | Level 3 | Mechanistically derived from established molecular biology; not yet validated in human ASD tissue |
| MSC therapy for State 2/3 | Level 3 | Phase I trial signals; mouse model evidence; mechanistic rationale strong |
The three-state model is mechanistically derived but not yet directly validated in human ASD SST-14 interneuron tissue or cerebrospinal fluid. The neuropeptide cascade endpoints — particularly plasma oxytocin pulsatility and urinary VIP — require assay standardization before they can serve as validated biomarkers. The IMIG evidence base rests on a single published clinician's experience. The constitutional susceptibility architecture (seven tipping points) carries Level 4 evidence for ASD-specific application at Tipping Points 1 and 4 — requiring prospective validation.
SST-14 interneurons in immune-dysregulated ASD are silenced by loss of the cAMP→PKA→CREB transcriptional drive through two converging mechanisms: NF-κB-mediated CREB suppression driven by chronic cytokine exposure, and Gαi-coupled adenosine receptor suppression of adenylyl cyclase driven by CD26 blockade. The downstream neuropeptide cascade — oxytocin, VIP, secretin — loses its upstream coordination simultaneously, producing the social, sensory, sleep, and gastrointestinal phenotype cluster of immune-derived ASD.
Restoring the cAMP→PKA→CREB→SST-14 transcriptional drive is the proximal therapeutic objective; neuropeptide cascade recovery is the measure of success. IVIG and IMIG address this by removing the NF-κB-activating cytokine load; IMIG does so at approximately 5% of IVIG's cost. MSC therapy addresses the metabolic exhaustion and structural recovery dimensions that immunoglobulin therapy alone cannot reach. The adjunct protocol provides the metabolic infrastructure without which upstream intervention cannot produce sustained recovery.
Three decades of clinical trial failures — secretin, oxytocin, IVIG, MSC in unselected populations — are not evidence of therapeutic futility. They are evidence that downstream neuropeptide replacement cannot succeed when the upstream SST-14 interneuron silencing that disrupted neuropeptide coordination remains unaddressed, and that unselected enrollment dilutes the responsive subgroup to statistical insignificance. The cAMP→PKA→CREB→SST-14 transcriptional drive must be restored before the downstream cascade can flow. The biomarker identifies which mechanism has silenced it. The trial tests whether restoring it recovers the cascade.
Full reference list (62 references) available in the working paper document. Key references shown above.
Medical Disclaimer: This working paper presents a mechanistic hypothesis for scientific discussion. It does not constitute medical advice, a treatment protocol, or a clinical recommendation. All therapeutic decisions must be made by qualified healthcare professionals with direct knowledge of the individual patient. Large-scale validation studies are required before any component of this framework can be considered established clinical practice.